Company Overview

MaxCyte, Inc. is a cell-engineering and life sciences technology company focused on enabling the development and commercialization of advanced cell-based therapies. The company operates primarily within the biotechnology and cell therapy industries, providing proprietary electroporation technology platforms and related services used in cell and gene therapy development, biologics discovery, and therapeutic manufacturing. Its core revenue drivers include sales and leases of its ExPERT instrument platforms, consumable processing assemblies, and strategic platform licenses tied to clinical and commercial programs.

The company serves biotechnology companies, pharmaceutical manufacturers, academic research institutions, and cell therapy developers globally. MaxCyte’s technology is positioned around non-viral cell engineering, which is viewed by many developers as a scalable alternative to viral-vector approaches for certain applications. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte evolved from an electroporation-focused research company into a commercial platform provider supporting engineered cell therapy programs, including CAR-T, TCR, stem cell, and gene-editing applications. Its growth has been supported by long-term strategic platform licenses with major biotechnology and pharmaceutical partners.

Business Operations

MaxCyte organizes its operations primarily around its cell-engineering platform business. Its flagship ExPERT platform includes instruments such as the ExPERT ATx, ExPERT STx, and ExPERT GTx, which are designed to enable scalable transfection and cell engineering across research, clinical, and commercial manufacturing settings. The company generates revenue from instrument sales and leasing arrangements, recurring consumable sales, software and support services, and milestone or licensing payments associated with strategic platform agreements.

The company operates in both domestic and international markets, with commercial activity across North America, Europe, and parts of the Asia-Pacific region. MaxCyte controls a portfolio of electroporation-related intellectual property and proprietary flow electroporation technology used for high-efficiency delivery of nucleic acids and other molecules into cells. The company has established strategic relationships with numerous cell therapy developers and pharmaceutical firms through platform license agreements that may include preclinical support, clinical development access, and potential commercial rights. Public disclosures identify collaborations with companies involved in CAR-T therapies, CRISPR-based editing, and engineered immune cell platforms.

Strategic Position & Investments

MaxCyte’s strategic direction centers on expanding adoption of non-viral cell engineering technologies in the growing cell and gene therapy market. The company has focused on increasing the number of Strategic Platform License agreements, which can provide long-duration recurring revenue opportunities tied to customer clinical advancement and commercialization milestones. Management has emphasized positioning MaxCyte as an enabling infrastructure provider rather than a direct therapeutic developer, allowing the company to participate broadly across multiple therapeutic programs and modalities.

A notable strategic development was the acquisition of SeQure Dx in 2023, which expanded MaxCyte’s capabilities into genomic editing safety and off-target risk assessment services. This acquisition aligned with broader industry demand for validation and analytical support in gene-editing applications. MaxCyte has also continued investing in applications supporting CRISPR-based editing, engineered immune cells, induced pluripotent stem cells, and next-generation biologics discovery. The company’s investments have been directed toward platform scalability, regulatory-compliant manufacturing support, and strengthening long-term partnerships with biotechnology and pharmaceutical customers.

Geographic Footprint

MaxCyte is headquartered in Rockville, Maryland, and maintains operations supporting customers across multiple global biotechnology hubs. The company’s commercial presence is strongest in the United States and Europe, where much of the global cell and gene therapy development industry is concentrated. It also serves customers in the Asia-Pacific region, including companies and research institutions involved in advanced therapeutic development.

Its international footprint is primarily driven through direct commercial operations, strategic collaborations, distributor relationships, and support infrastructure tied to clinical-stage and commercial-stage cell therapy manufacturing. The company’s technology platforms are utilized by organizations conducting clinical development and manufacturing activities in several countries, reflecting the increasingly global nature of the cell therapy industry.

Leadership & Governance

MaxCyte’s leadership team has emphasized long-term platform adoption, recurring consumable revenue growth, and expansion of strategic licensing relationships with therapy developers. The company operates with a technology-enablement strategy focused on supporting a broad ecosystem of therapeutic innovators rather than concentrating on a single therapeutic pipeline.

Key executives include:

• Maher Masoud – President and Chief Executive Officer
• Douglas Doerfler – Former President and Chief Executive Officer
• David J. McDonald – Chief Financial Officer
• Thomas M. Ross – Executive Vice President, Global Sales
• Anette Nordvall – Chief Operating Officer
• William “Chip” Baird – Chief Commercial Officer

The company’s governance structure includes a board with experience spanning biotechnology, medical technology, pharmaceutical commercialization, and capital markets. Leadership communications in public filings and investor materials have consistently emphasized operational scalability, strategic partnerships, and enabling next-generation cell-engineering applications through platform-based business expansion.